Aimalohi A Ahonkhai1,2,3,4,5, Bolanle Banigbe6, Juliet Adeola6, Ingrid V Bassett3,4,5,7, Ifeoma Idigbe8, Prosper Okonkwo6, Kenneth A Freedberg3,4,5,7,9,10, Susan Regan4,7,10, Elena Losina4,5,11,12. 1. Division of Infectious Disease, Vanderbilt University Medical Center, Nashville, TN. 2. Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN. 3. Division of Infectious Disease, Massachusetts General Hospital, Boston, MA. 4. Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA. 5. Harvard Medical School, Boston, MA. 6. AIDS Prevention Initiative in Nigeria (APIN), Abuja, Nigeria. 7. Harvard University Center for AIDS Research (CFAR), Boston, MA. 8. Nigerian Institute for Medical Research, Lagos, Nigeria. 9. Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA. 10. Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA. 11. Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA. 12. Department of Biostatistics, Boston University School of Public Health, Boston, MA.
Abstract
BACKGROUND: Medication possession ratio (MPR) is widely used as a measure of adherence to antiretroviral therapy (ART). Many adolescents and young adults (AYA) experience ART adherence challenges. Our objective was to determine whether the relationship between MPR and virologic failure (VF) is consistent between AYA and older adults in Nigeria. METHODS: We conducted a retrospective study of AYA (aged 15-25 years) and adults (aged >25 years) who initiated ART between January 2009 and December 2012 at 10 university-affiliated HIV clinics in Nigeria. We used multivariate generalized linear models to assess the relationship between age, MPR (ART doses dispensed)/(days since ART initiation), and risk of VF (HIV RNA >1000 copies/mL) in the 1st year on ART. RESULTS: The cohort included 1508 AYA and 11,376 older adults. VF was more common in AYA than older adults (30% vs. 24% P < 0.01). Overall, 74% of patients had optimal, 16% suboptimal, and 9% poor adherence (MPR >94%, 80%-94%, and <80%, respectively). AYA attended fewer pharmacy-only visits than older adults (5 vs. 6, P < 0.001). Higher MPR was associated with decreased rate of VF (80%-94%, accounting rate of return 0.57; >94% accounting rate of return 0.43, P < 0.001 vs. MPR <80%). Among those with optimal adherence by MPR, 26% of AYA had VF, a risk that was 20% higher than for older adults with optimal adherence (P < 0.001). CONCLUSIONS: In this Nigerian cohort, MPRs were high overall, and there was a strong association between low MPR and risk of VF. Nonetheless, 26% of AYA with high MPRs still had VF. Understanding the discrepancy between MPR and viral suppression in AYA is an important priority.
BACKGROUND: Medication possession ratio (MPR) is widely used as a measure of adherence to antiretroviral therapy (ART). Many adolescents and young adults (AYA) experience ART adherence challenges. Our objective was to determine whether the relationship between MPR and virologic failure (VF) is consistent between AYA and older adults in Nigeria. METHODS: We conducted a retrospective study of AYA (aged 15-25 years) and adults (aged >25 years) who initiated ART between January 2009 and December 2012 at 10 university-affiliated HIV clinics in Nigeria. We used multivariate generalized linear models to assess the relationship between age, MPR (ART doses dispensed)/(days since ART initiation), and risk of VF (HIV RNA >1000 copies/mL) in the 1st year on ART. RESULTS: The cohort included 1508 AYA and 11,376 older adults. VF was more common in AYA than older adults (30% vs. 24% P < 0.01). Overall, 74% of patients had optimal, 16% suboptimal, and 9% poor adherence (MPR >94%, 80%-94%, and <80%, respectively). AYA attended fewer pharmacy-only visits than older adults (5 vs. 6, P < 0.001). Higher MPR was associated with decreased rate of VF (80%-94%, accounting rate of return 0.57; >94% accounting rate of return 0.43, P < 0.001 vs. MPR <80%). Among those with optimal adherence by MPR, 26% of AYA had VF, a risk that was 20% higher than for older adults with optimal adherence (P < 0.001). CONCLUSIONS: In this Nigerian cohort, MPRs were high overall, and there was a strong association between low MPR and risk of VF. Nonetheless, 26% of AYA with high MPRs still had VF. Understanding the discrepancy between MPR and viral suppression in AYA is an important priority.
Authors: S Bakken; W L Holzemer; M A Brown; G M Powell-Cope; J G Turner; J Inouye; K M Nokes; I B Corless Journal: AIDS Patient Care STDS Date: 2000-04 Impact factor: 5.078
Authors: James H McMahon; Michael R Jordan; Karen Kelley; Silvia Bertagnolio; Steven Y Hong; Christine A Wanke; Sharon R Lewin; Julian H Elliott Journal: Clin Infect Dis Date: 2011-01-18 Impact factor: 9.079
Authors: Jessica E Haberer; Nicholas Musinguzi; Yap Boum; Mark J Siedner; A Rain Mocello; Peter W Hunt; Jeffrey N Martin; David R Bangsberg Journal: J Acquir Immune Defic Syndr Date: 2015-12-01 Impact factor: 3.731
Authors: Lisa B Hightow-Weidman; Kathryn E Muessig; Jose Bauermeister; Chen Zhang; Sara LeGrand Journal: Curr HIV/AIDS Rep Date: 2015-12 Impact factor: 5.071
Authors: Moses R Kamya; Harriet Mayanja-Kizza; Andrew Kambugu; Sabrina Bakeera-Kitaka; Fred Semitala; Patricia Mwebaze-Songa; Barbara Castelnuovo; Petra Schaefer; Lisa A Spacek; Anne F Gasasira; Elly Katabira; Robert Colebunders; Thomas C Quinn; Allan Ronald; David L Thomas; Adeodata Kekitiinwa Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: Matthew P Fox; Gilles Van Cutsem; Janet Giddy; Mhairi Maskew; Olivia Keiser; Hans Prozesky; Robin Wood; Miguel A Hernán; Jonathan A C Sterne; Matthias Egger; Andrew Boulle Journal: J Acquir Immune Defic Syndr Date: 2012-08-01 Impact factor: 3.731
Authors: Raphael Z Sangeda; Fausta Mosha; Mattia Prosperi; Said Aboud; Jurgen Vercauteren; Ricardo J Camacho; Eligius F Lyamuya; Eric Van Wijngaerden; Anne-Mieke Vandamme Journal: BMC Public Health Date: 2014-10-04 Impact factor: 3.295
Authors: Babafemi O Taiwo; Kehinde M Kuti; Lisa M Kuhns; Olayinka Omigbodun; Olutosin Awolude; Adedotun Adetunji; Baiba Berzins; Patrick Janulis; Amy K Johnson; Ogochukwu Okonkwor; Bibilola D Oladeji; Abigail Muldoon; Olubusuyi M Adewumi; Paul Amoo; Hannah Atunde; Bill Kapogiannis; Robert Garofalo Journal: J Acquir Immune Defic Syndr Date: 2021-08-01 Impact factor: 3.771
Authors: Aima A Ahonkhai; Leslie J Pierce; Samuel Mbugua; Benjamin Wasula; Samuel Owino; Ashley Nmoh; Ifeoma Idigbe; Oliver Ezechi; Sandra Amaral; Agatha David; Prosper Okonkwo; Nadia Dowshen; Martin C Were Journal: Front Reprod Health Date: 2021-07-30
Authors: Moses K Nyongesa; Mwaganyuma H Mwatasa; Vincent A Kagonya; Gabriel Mwambingu; Caroline Ngetsa; Charles R J C Newton; Amina Abubakar Journal: BMC Infect Dis Date: 2022-05-11 Impact factor: 3.667
Authors: Sharon Tsui; Caitlin E Kennedy; Lawrence H Moulton; Larry W Chang; Jason E Farley; Kwasi Torpey; Eric van Praag; Olivier Koole; Nathan Ford; Fred Wabwire-Mangen; Julie A Denison Journal: Trop Med Int Health Date: 2021-08-08 Impact factor: 2.622